Preparation method and application of rhizoma atractylodis volatile oil microemulsion

By preparing volatile oil microemulsion of Atractylodes, the shortcomings of traditional antidepressants were solved, the water solubility and bioavailability of volatile oil of Atractylodes were improved, the basis and mechanism of action of its medicinal effect were clarified, and new treatment ideas for the treatment of depression were provided. The research and development direction of high-value-added products.

CN119074657APending Publication Date: 2024-12-06CHANGCHUN UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411173820.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively solve the treatment of depression, especially because traditional antidepressant drugs have problems such as slow onset, severe adverse reactions, high prices, easy recurrence and many side effects, and at the same time, the antidepressant mechanism of volatile oil of Atractylodes and The basis for the effectiveness has not been clarified.

Method used

Using the microemulsification technology of Atractylodes volatile oil, O/W type Atractylodes volatile oil microemulsification is prepared by selecting appropriate surfactants and cosurfactants to improve their water solubility and bioavailability, and combined with GC-MS analysis and network pharmacology , clarify the basis of the drug effect and molecular mechanism of action, and use animal models to explore its efficacy in relieving depression and calming the nerves.

Benefits of technology

It significantly improves the water solubility and bioavailability of volatile oils of Atractylodes, simplifies the preparation process, reduces costs, improves product stability, and provides theoretical support for the research and development of antidepressants through neurochemical tests and signaling pathway research, and enhances the The clinical application effect of traditional Chinese medicine in the treatment of depression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074657A_ABST
    Figure CN119074657A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of rhizoma atractylodis volatile oil microemulsion, and relates to the technical field of microemulsion, the preparation method comprises the following steps: S1, selecting a surfactant and a cosurfactant, and mixing to form a mixed surfactant; and S2, mixing the rhizoma atractylodis essential oil with the mixed surfactant according to a mass ratio, and preparing the microemulsion through a titration method. By preparing the O / W type rhizoma atractylodis volatile oil microemulsion, the problems that volatile oil is poor in water solubility and easy to volatilize are solved. The solubility of the volatile oil in water is improved, the bioavailability of the volatile oil is remarkably enhanced, the drug effect of the volatile oil is fully played, the drug effect of the volatile oil for soothing nerves and resisting depression is remarkably enhanced, the nerve soothing effect of the volatile oil is derived from the calming effect of a central nervous system and the regulation of neurotransmitters, and the improvement of sleep quality and emotion balance is facilitated. Meanwhile, the active ingredients in the volatile oil microemulsion can play an anti-depression effect through a multi-target action mechanism, including neuroprotection, emotion regulation and the like, and a new choice is provided for treatment of mental health problems such as depression and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microemulsions, in particular to a preparation method of atractylodes lancea volatile oil microemulsion and application thereof. Background Art

[0002] Depressive disorder is the most common mental illness that endangers human health. Clinically, it can be seen that the core symptom groups include low mood that is not commensurate with the situation, loss of interest, and loss of pleasure; psychological syndromes such as slow thinking and cognitive impairment; and physical symptom groups such as sleep disorders and body pain. With the rapid development of social economy, fierce social competition, increasingly accelerated pace of life, and complex and changeable interpersonal relationships, people's stress has increased dramatically, and they are prone to mental illness. The incidence of depression has increased year by year and is called "mental cold". According to the World Health Organization's prediction, by 2030, depression will become the first in the global disease burden (WHO document EB130 / 9, 2011). Depressive disorders seriously affect people's physical and mental health, so the study of depression has become a hot topic in the medical field. Research on the pathogenesis and prevention of depression is becoming increasingly important, but its pathogenesis has not yet been fully elucidated. The causes of depression are complex, mainly including genetics, environmental stress, endocrine disorders and low immunity. According to literature reports: the pathogenesis of depression is mainly studied from the aspects of hypothalamic-pituitary-adrenal axis (HPA) dysfunction, blood-brain barrier damage, oxidative stress, mitochondrial dysfunction, inflammatory response, hippocampal neuron apoptosis, etc. Among them, the mechanism of hippocampal neuron apoptosis is complex and there is no clear conclusion at present. At present, the treatment of depression is mainly divided into psychotherapy and drug therapy. Among them, drug therapy is mainly based on central antidepressants such as tricyclic antidepressants (TCAs), monoamine oxidase inhibitors, and new 5-hydroxytryptamine (5-HT) reuptake inhibitors (SSRIs). However, these antidepressants generally have the disadvantages of slow onset, serious adverse reactions, high price, easy relapse after discontinuation of medication, and more side effects.

[0003] Depression is a disease name in modern medicine. Although this disease name has never been recorded in ancient documents, the spirits, yang-dominant yin-following, depression, zang-mania, and epilepsy recorded in ancient books have many similarities with the clinical manifestations and diagnosis of depression. The Yellow Emperor's Internal Classic records the spirits hidden in the five zang organs. The "five zang-organ spirits" are the heart spirit, lung spirit, liver spirit, spleen spirit, and kidney spirit. They can transform into five wills and seven emotions, which are similar to the soul in the human body. If the "five zang-organ spirits" are abnormal, people will have depression symptoms such as loss of appetite, insomnia, anxiety, sluggish thinking, and low mood. Depression should be classified as "depression" and "zang-mania" in traditional Chinese medicine. The main pathogenesis is that the liver fails to vent, the spleen fails to function properly, and the heart fails to be nourished. Traditional Chinese medicine mainly treats soothing the liver and relieving depression, and strengthening the brain and calming the mind as the main treatment principles, which has obvious advantages in the treatment of depression. Guo Xiaoqing et al. divided depression into liver qi stagnation type, liver fire ascending type, qi stagnation and phlegm accumulation type, qi stagnation and blood stasis type, qi and blood deficiency type, yin deficiency and internal heat type and yang deficiency and cold dampness type. In addition, insomnia is also one of the important risk factors for depression, and the two often occur together. The pathogenesis of depression-comorbid insomnia (DCI) is very complex. It is currently believed to be related to multiple factors such as neuroendocrine dysfunction, monoamine neurotransmitter imbalance, and neural plasticity damage. Depression-comorbid insomnia often manifests as difficulty falling asleep, easy awakening, low mood, lack of energy and laziness, and decreased appetite. Its main pathogenesis is also liver depression and spleen deficiency. Modern clinical research has found that the treatment of depression using antidepressant drugs combined with acupuncture therapy, emotional therapy, Chinese medicine aromatherapy inhalation therapy and health-preserving exercises has few side effects and low dependence; for the treatment of major depression, it can be used in combination with Western medicine to reduce the adverse reactions of Western medicine and simultaneously treat other complications of depression to achieve a synergistic effect.

[0004] Aromatic Chinese medicine is a kind of Chinese herbal medicine with aromatic smell and volatility. It has a fragrant smell, pungent and rising, conforming to the nature of liver wood strips to rise, and can help the rise and release of liver qi; it is good for the spleen and stomach, can remove stagnation, disperse the accumulation, and make the spleen function healthily; it can enter the heart meridian, open the heart qi, and calm the mind and improve the restlessness caused by emotional frustration. Therefore, aromatic Chinese medicine has great advantages in the treatment of depression. In recent years, Chinese medicine aromatherapy is in the ascendant. It has become a powerful supplement to traditional medical methods because of its simple operation and obvious efficacy. The small molecule components of volatile oils unique to aromatic Chinese medicines can enter the brain directly after nasal inhalation, regulate the autonomic nervous system or endocrine system, play the role of stabilizing emotions, and have unique advantages in regulating emotional activities. The inhalation of essential oils of medicinal materials such as agarwood, Chuanxiong and Perilla has a sedative and hypnotic effect. The volatile oil of Artemisia argyi can also enhance the activity of brain areas related to emotions in normal rats, improve the motor ability of depressed animals, and have a clear anti-depressant effect. Atractylodes lancea is the dried rhizome of Atractylodes lancea (Thunb.) DC. or Atractylodes chinensis (DC.) Koidz. of the Asteraceae family. It is a commonly used dehumidifying drug in clinical practice, with the effects of drying dampness and strengthening the spleen, dispelling wind and cold, and improving eyesight. In ancient books and documents of various dynasties, Atractylodes lancea is the first choice of drugs for expelling evil spirits and warding off epidemics because of its aromatic and dry aroma, which can invigorate the positive energy and cleanse the evil spirits. It is also aromatic and warm, which can warm the middle and wake up the spleen, eliminate accumulation and resolve stagnation. It can be used clinically for symptoms such as spleen and stomach food stagnation, stomach fullness, nausea and vomiting, and poor appetite. In modern clinical applications, the wide application of classic prescriptions such as Pingwei San has made the "drying dampness effect" of Atractylodes lancea famous in the world, while its "qi-promoting, depression-relieving and mind-calming effect" has been neglected. In fact, doctors of all dynasties have long recognized that Atractylodes lancea has a good effect of promoting qi and relieving depression. "Suwen Zhizhen Yao Da Lun" says that "spicy and sweet dispersing is yang". Spiciness belongs to yang, and yang is active and ascending, so Atractylodes lancea tastes pungent and ascending. "Bencao Wenda" says that Atractylodes lancea "is green in color, has the nature of wood, and can be more dredging." "Bencao Beiyao" says that Atractylodes lancea "raises yang and relieves depression." "Compendium of Materia Medica" calls it "immortal art". Atractylodes lancea has a fragrant smell and is good at moving but not staying, so it has the effect of promoting qi and relieving depression. "Yuzhou Yaojie" says: "Atractylodes lancea moves but does not stay, drains water and relieves depression, and Atractylodes lancea is the best"; "Bencao Zhengyi" also says: "Atractylodes lancea has a strong smell, which is more powerful than Atractylodes lancea, and can penetrate from top to bottom", among which Atractylodes lancea volatile oil plays a major role in relieving depression. Zhu Danxi pointed out that Atractylodes can relieve all kinds of depression, and created a prescription for relieving all kinds of depression, Yueju Pills, which uses Atractylodes, Shenqu, Chuanxiong, Gardenia, Cyperus, Crataegus, and Malt to "treat six types of depression, chest and diaphragm fullness, or acid regurgitation and vomiting, and indigestion. This is a holy medicine for treating depression." Later generations based on this, such as the Reyu Decoction in "Danxi's Heart Method", the Shiyu Decoction and Qiyu Decoction in "Zhengzhi Zhunsheng", and the Shiyu Decoction in "Zuobingyuanliu Xizhu", all of which take the meaning of Atractylodes's pungent nature to relieve depression. Modern pharmacological studies have shown that Atractylodes-related compound preparations have good antidepressant effects, but there are no relevant reports on the antidepressant effects and specific mechanisms of Atractylodes volatile oils, and the material basis of the efficacy is still unclear.The volatile oil of Atractylodes lancea has a fragrant smell, stable medicinal properties, low irritation, and no toxic side effects on the human body. In-depth research on its pharmacological effects of relieving depression and calming the mind, further exploration of its material basis and mechanism of action can fully tap its potential as an auxiliary means of synergistic treatment of mood disorders.

[0005] At present, microencapsulation and microemulsification of Atractylodes lancea volatile oil are the two most commonly used methods to improve its bioavailability. However, microencapsulation technology has problems such as cumbersome operation, high cost, and large product particle size. Microemulsion is a transparent or translucent, low-viscosity, and thermodynamically stable liquid-liquid dispersion system spontaneously formed by oil phase, water phase, surfactant, and co-surfactant in a certain proportion. It has the characteristics of small and uniform particle size, clear and transparent appearance, simple preparation, and stable performance. Therefore, making Atractylodes lancea volatile oil into oil-in-water (O / W) microemulsion can not only improve the water solubility of Atractylodes lancea volatile oil and reduce its volatility, but also reduce costs, improve its deep processing utilization rate and economic value. However, there are few reports on the research of Atractylodes lancea volatile oil microemulsion. This study used Atractylodes lancea volatile oil as the oil phase, explored the preparation conditions of O / W type Atractylodes lancea volatile oil microemulsion and tested and analyzed its performance, in order to improve the water solubility of Atractylodes lancea volatile oil, reduce its volatility, improve its stability, and facilitate storage and transportation, further improve its application value, and provide theoretical support for the development of high value-added products of Atractylodes lancea volatile oil.

[0006] In view of this, this project established the gas chromatography-mass spectrometry (GC-MS) fingerprint of Atractylodes lancea volatile oil, analyzed the chemical composition of Atractylodes lancea volatile oil, clarified its pharmacodynamic material basis and controlled its quality; on this basis, it bridged network pharmacology to further anchor the pharmacodynamic material basis and molecular mechanism of action of Atractylodes lancea volatile oil in antidepressant and tranquilizing effects; combined with the chronic mild unpredictable stimulation (CUMS) rat depression model and the chlorophenylalanine (PCPA) mouse insomnia model, aromatherapy was used to explore the depression-relieving and tranquilizing effects of Atractylodes lancea volatile oil through animal behavior and neurochemical experiments, and its mechanism of action was revealed based on the brain derived neurotrophic factor (BDNF) / cAMPresponse element binding protein (CREB) signaling pathway, in order to provide a theoretical basis and new ideas for further clarifying the pathogenesis and auxiliary treatment of depression, and also lay a theoretical foundation for the research and development of Atractylodes lancea volatile oil as a new auxiliary antidepressant and comorbid insomnia drug. Summary of the invention

[0007] In order to solve the above problems, that is, to solve the problems raised by the above background technology, the present invention proposes a method for preparing a microemulsion of atractylodes lancea volatile oil and its application, which comprises the following steps: S1, selecting a surfactant and a co-surfactant and mixing them to form a mixed surfactant; S2, mixing the atractylodes lancea essential oil and the mixed surfactant in different mass ratios, and preparing a microemulsion by titration.

[0008] The present invention is further configured as follows: the surfactant is selected from one or more of Tween-80, Tween-60, EL-35 and EL-30.

[0009] The present invention is further configured as follows: the co-surfactant is selected from one or more of anhydrous ethanol, PEG-400, propylene glycol and glycerol.

[0010] The present invention is further configured as follows: the surfactant and the co-surfactant are uniformly mixed in a mass ratio of 2:1.

[0011] The present invention is further configured as follows: the mixed surfactant and the Atractylodes lancea essential oil are mixed in a mass ratio of 1-9:9-1 respectively.

[0012] The invention is further configured as follows: using Atractylodes lancea volatile oil as the oil phase, deionized water as the water phase, Tween-80 as the surfactant, anhydrous ethanol as the co-surfactant, and the optimal Km value is 2.

[0013] The present invention is further configured as follows: the microemulsion solution is uniform, clear and transparent.

[0014] The present invention is further configured as follows: the Atractylodes lancea volatile oil microemulsion is used as a composition for assisting in the treatment of sedation and depression.

[0015] The beneficial technical effect of the present invention is: by preparing an O / W type atractylodes lancea volatile oil microemulsion, the water solubility and bioavailability of atractylodes lancea volatile oil can be significantly improved, while reducing its volatility. Microemulsion technology not only simplifies the preparation process, reduces costs, but also improves the stability of the product. In addition, through GC-MS fingerprint and network pharmacology research, the material basis of the efficacy can be clarified, and the modernization and standardization of traditional Chinese medicine can be promoted. The combination of animal models and neurochemical experiments provides a new treatment idea for the depression-relieving and tranquilizing efficacy of atractylodes lancea volatile oil. At the same time, studying the BDNF / CREB signaling pathway helps to reveal its mechanism of action and provide theoretical support for the research and development of antidepressant drugs.

[0016] In-depth research on the efficacy and mechanism of Atractylodes lancea volatile oil can promote its development and application as a high value-added product, and through modern pharmacological research, enhance the clinical application of traditional Chinese medicine in the treatment of depression, improve the therapeutic effect, reduce side effects, and significantly enhance its tranquilizing and antidepressant efficacy. Its tranquilizing effect originates from the sedative effect on the central nervous system and the regulation of neurotransmitters, which helps to improve sleep quality and emotional balance. At the same time, the active ingredients in volatile oil microemulsions may exert antidepressant effects through multi-target mechanisms, including neuroprotection, emotional regulation, etc., providing new options for the treatment of mental health problems such as depression. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The total ion flow diagram of Atractylodes lancea essential oil is shown.

[0018] Figure 2 The pseudo-ternary phase diagram formed by different surfactants is shown.

[0019] Figure 3 The pseudo-ternary phase diagram formed by different co-surfactants is shown.

[0020] Figure 4 The pseudo-ternary phase diagram formed by different Km is shown.

[0021] Figure 5 The particle size distribution of the Atractylodes lancea volatile oil microemulsion is shown.

[0022] Figure 6 The Venn diagram of common targets of Atractylodes lancea and insomnia is shown.

[0023] Figure 7 The PPI network diagram of potential targets of Atractylodes macrocephala for treating insomnia is shown.

[0024] Figure 8 The GO enrichment analysis diagram of Atractylodes macrocephala in treating insomnia is shown.

[0025] Fig. 9 The KEGG enrichment analysis diagram of Atractylodes macrocephala in treating insomnia is shown.

[0026] Fig.10 The figure shows the morphological changes of mouse brain tissue.

[0027] Fig.11 Shows the changes in 5-HT, Glu, GABA, TNF-α, IL-2, and IL-6 in insomnia model mice picture.

[0028] Fig.12 Shows the mRNA expression level of the target gene in insomnia model mice picture.

[0029] Fig.13Shows the protein expression levels of insomnia model mice picture.

[0030] Fig.14 A graph showing the autonomic activity of rats in a mine field experiment for depression treatment. DETAILED DESCRIPTION

[0031] Please refer to the attached Figure 1-14 Those skilled in the art should understand that these embodiments are only used to explain the technical principles of the present invention and are not intended to limit the protection scope of the present invention.

[0032] The present invention provides a method for preparing a microemulsion of volatile oil of Atractylodes macrocephala, comprising the following steps:

[0033] 1. Analysis of volatile oil components of Atractylodes lancea based on GC-MS

[0034] The GC-MS method was used to obtain the total ion current of the volatile oil, analyze the components of Atractylodes lancea, and identify the chemical components. The obtained data results were retrieved by matching the NIST11 spectral library, and then combined with relevant literature to perform manual mass spectrum analysis to determine the compounds, and the peak area normalization method was used to determine their relative contents.

[0035] 1. Preparation of Atractylodes macrocephala volatile oil

[0036] Add distilled water to the Atractylodes lancea powder at a solid-liquid ratio of 1:8, soak in ultrasound for 1 hour, heat at a constant temperature in an electric heating mantle, and perform steam distillation for 5 hours according to Appendix (Method A) of the General Rules 2204 of the 2020 Edition of the Chinese Pharmacopoeia (Volume 4) until no volatile oil drips out. Cool quietly for 1 hour, and dehydrate with sodium chloride to obtain the Atractylodes lancea volatile oil.

[0037] 2. Gas chromatography conditions

[0038] Agilent HP-5MS column (30m×250μm×0.25μm), heating program: initial temperature 45℃, run for 2min; heat to 280℃ at 5℃ / min, run for 10min; total run time 59min. Quencher He, flow rate 2.2mL / min; impactor N 21.5mL / min; injection mode: splitless; injection port temperature 250℃; injection volume 1μL.

[0039] 3. Mass spectrometry conditions

[0040] Ion source EI, electron bombardment energy 70Ev; ion source temperature 230°C; scanning mass range m / z 40-500; solvent delay time 3min; solvent removal time 5min; NIST-20 standard mass spectrum library.

[0041] 4. Preparation of test solution

[0042] Take 100 μl of the test sample, add 900 μl of ethyl acetate, vortex to mix, and use it as the test solution.

[0043] 5. GC-MS results

[0044] GC-MS analysis of total ion flow chart of Atractylodes lancea volatile oil, see Figure 1 After searching, matching and manual analysis of the NIST11 standard database, a total of 50 chemical components were identified, as shown in Table 1. They mainly include alcohols, aromatic hydrocarbons, olefins, esters and ketones.

[0045] Table 1: Chemical components of volatile oil from Atractylodes macrocephala determined by GC-MS

[0046]

[0047]

[0048]

[0049] 2. Preparation and quality evaluation of Atractylodes lancea volatile oil microemulsion

[0050] Microemulsion was prepared by titration method. The best formula was determined by selecting different surfactants and co-surfactants and adjusting the Km value, and the pseudo-ternary phase diagram was used to evaluate the quality of the prepared microemulsion from the aspects of type determination, temperature stability test, centrifugal stability test and physical property evaluation.

[0051] 1. Drawing of pseudo-ternary phase diagram of microemulsion

[0052] The microemulsion was prepared by titration. The surfactant and the co-surfactant were first stirred evenly in a certain proportion, and then the mixture was mixed with the essential oil of Atractylodes lancea in a mass ratio of 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9, respectively. The mixture of the three components was titrated with distilled water under stirring with a constant temperature magnetic stirrer. The changes in the appearance of the system were observed until a clear and transparent microemulsion was formed, that is, the change point where the entire system changed from turbid to clear and transparent and then to turbid, and the amount of water added was recorded to determine the critical point of microemulsion formation. According to the determined critical point, the pseudo-ternary phase diagram was drawn using Origin2021 software with the oil phase (O) of Atractylodes lancea volatile oil, the deionized water phase (W) and the mixed surfactant as the three vertices of the pseudo-ternary phase diagram.

[0053] 2. Screening of microemulsion prescription

[0054] (1) Selection of surfactant

[0055] At room temperature, four non-toxic nonionic surfactants, Tween-80, Tween-60, EL-35 and EL-30, were selected to prepare microemulsions of Atractylodes lancea volatile oil. These four surfactants were mixed with anhydrous ethanol at a mass ratio of 2:1 as mixed surfactants. Water was added evenly and titrated slowly under magnetic stirring. The microemulsion solution was uniform, clear and transparent. A pseudo-ternary phase diagram was drawn to determine the best surfactant.

[0056] (2) Selection of co-surfactant

[0057] At room temperature, the co-surfactants selected were anhydrous ethanol, PEG-400, propylene glycol, and propylene glycol. The preferred surfactants were uniformly mixed with the four co-surfactants at a mass ratio of 2:1, and a pseudo-ternary phase diagram was drawn to determine the best co-surfactant.

[0058] (3) Screening of Km value

[0059] At room temperature, the optimal surfactant and co-surfactant are selected to prepare microemulsions. The Km values ​​are selected as 0.5, 1, 2 and 3 respectively, and a pseudo-ternary phase diagram is drawn to determine the optimal Km value.

[0060] 3. Quality evaluation of O / W microemulsion of Atractylodes lancea volatile oil

[0061] (1) Determination of microemulsion type

[0062] The prepared Atractylodes lancea volatile oil microemulsion was subjected to a dyeing experiment. Take a small amount of Atractylodes lancea volatile oil microemulsion, add equal amounts of Sudan red and methylene blue, and observe the diffusion rate of the dye in the microemulsion. Sudan red diffuses quickly, which is an oil-in-water type, and vice versa, it is a water-in-oil type.

[0063] (2) Temperature stability test

[0064] Take a small amount of Atractylodes lancea volatile oil microemulsion and place it in a constant temperature water bath at 15, 25, 35 and 45°C for 20 minutes respectively, and observe its appearance. If there is no stratification or turbidity in the appearance, it means that the microemulsion is stable, otherwise it is unstable.

[0065] (3) Centrifugal stability test

[0066] At room temperature, take equal amounts of Atractylodes lancea volatile oil microemulsion and centrifuge at 1000, 2000, 3000 and 4000 r / min for 20 min, and observe its appearance. If there is no stratification or turbidity in the appearance, it means that the microemulsion is stable, otherwise it is unstable.

[0067] (4) Physical properties of microemulsions

[0068] At room temperature, the particle size, polydispersity index (PDI) and pH value of the microemulsion were tested using a multi-angle particle size analyzer and a high-sensitivity Zeta potential instrument and a PHS-3CW acidity meter, respectively, and the measurements were repeated three times.

[0069] 3. Results of Microemulsion of Atractylodes lancea Volatile Oil

[0070] 1. Preparation conditions of Atractylodes lancea volatile oil microemulsion

[0071] (1) Effect of surfactants

[0072] With Atractylodes lancea volatile oil as the oil phase, deionized water as the water phase, anhydrous ethanol as the co-surfactant, and a Km value of 2, the effects of four different surfactants on the formation of the microemulsion system were investigated. The pseudo-ternary phase diagram is shown in Figure 2 (A. Tween-80; B. Tween-60; C. EL-35; D. EL-30.) The results show that among these four surfactants, the microemulsion area formed when Tween-80 is used as the surfactant is the largest, so Tween-80 is selected as the best surfactant.

[0073] (2) Effect of co-surfactant

[0074] The volatile oil of Atractylodes lancea was used as the oil phase, deionized water as the water phase, Tween-80 as the surfactant, and the Km value was 2. The preparation of microemulsions using four different co-surfactants was compared. The pseudo-ternary phase diagram is shown in Figure 3 (A. Anhydrous ethanol; B. Propylene glycol; C. Glycerol; D. Polyethylene glycol.), the order of the microemulsion areas formed by the four co-surfactants from large to small is anhydrous ethanol > 1,2-propylene glycol > glycerol > polyethylene glycol, so anhydrous ethanol is the best co-surfactant for preparing microemulsions of Atractylodes lancea volatile oil.

[0075] (3) Influence of Km value

[0076] With Atractylodes lancea volatile oil as the oil phase, deionized water as the water phase, Tween-80 as the surfactant, and anhydrous ethanol as the co-surfactant, four pseudo-ternary phase diagrams with different Km values ​​were drawn. Figure 4 (A.3; B.2; C.1; D.0.5.). When the Km value is within the range of 0.5-3, the area of ​​the microemulsion increases as the Km value increases. In addition, although the area of ​​the microemulsion formed when Km=3 is slightly larger than that when Km=2, when the Km value is 3, more gel phase will be produced during the formation of the microemulsion, the viscosity is too high, and the more surfactants there are, the greater the stimulation to the human body, and it is easier to produce foam, which is not conducive to the transportation of the later product. Therefore, the Km value of 2 is selected as the optimal Km value for preparing the microemulsion of Atractylodes lancea volatile oil.

[0077] 2. Microemulsion quality evaluation

[0078] (1) Appearance

[0079] The appearance of the Atractylodes lancea microemulsion was observed. The Atractylodes lancea volatile oil microemulsion prepared according to the prescription was yellow, uniform, transparent, clear in appearance, and had good fluidity.

[0080] (2) Identification of microemulsion types

[0081] By staining with Sudan red and methylene blue, it was observed that the diffusion rate of blue in the system was significantly faster than that of red, indicating that the microemulsion prepared by this method was O / W type.

[0082] (3) Temperature stability test

[0083] The results showed that after standing at 5, 15, 25, 35, and 45°C for 20 min, the microemulsion system remained clear and transparent without stratification or turbidity, indicating that the microemulsion has good temperature stability.

[0084] (4) Centrifugal stability test

[0085] The results showed that the microemulsion system remained clear and transparent, without stratification or precipitation, after centrifugation at 1000, 2000, 3000 and 4000 r / min for 20 min. No stratification or demulsification occurred, indicating that the microemulsion had good centrifugal stability.

[0086] (5) Physical properties

[0087] like Figure 5 As shown, the results showed that the particle size of the Atractylodes lancea volatile oil microemulsion was (159±4.53) nm, the PDI value was (0.451±0.012), and the pH value was 6.74±0.02.

[0088] 4. Construction of Network Pharmacology

[0089] 1. Experimental methods

[0090] (1) Acquisition of volatile oil targets from Atractylodes macrocephala

[0091] The STP database and TCMSP database were used to search for the above 50 chemical components, with oral bioavailability (OB ≥ 30%) and drug-like properties (DL ≥ 0.18) as screening criteria, and then the duplicate items were corrected and deleted through the UniProt database.

[0092] (2) Acquisition of insomnia targets

[0093] Insomnia-related targets were searched in drugbank, OMIM, and genecards databases, and the results were integrated and duplicate values ​​were removed to obtain insomnia-related targets.

[0094] (3) Construction of protein-protein interaction (PPI) network

[0095] Using R software, the obtained drug targets were mapped to disease targets, and the intersection was taken to obtain the potential targets of Atractylodes lancea volatile oil for the treatment of insomnia. A drug-disease Venn diagram was drawn, and the potential targets were imported into the STRING platform. The biological species was set to "Homo sapiens", the minimum interaction threshold was set to "highest confi-dence" (>0.9), and the other settings were set as default settings. Then the PPI network was obtained and visualized by Cytoscape 3.9.1 software to obtain the core targets.

[0096] (4) GO enrichment and KEGG pathway analysis

[0097] The key targets of Atractylodes lancea volatile oil for the treatment of insomnia were uploaded to the Metascape database for KEGG pathway and GO functional enrichment analysis. The projects with a corrected P value ≤ 0.01 were screened, sorted according to the corrected P value of the enriched genes, and the top 20 related signal pathways were selected. The above analysis was then visualized and a bubble chart was generated through the bioinformatics cloud platform (http: / / www.bioinformatics.com.cn / ).

[0098] 2. Experimental results

[0099] (1) Active ingredients in Atractylodes

[0100] The above 50 chemical components were searched using the STP database and the TCMSP database, with oral bioavailability (OB ≥ 30%) and drug-like properties (DL ≥ 0.18) as screening conditions, and then the UniProt database was used to correct and delete duplicate items. A total of 153 active ingredients were identified.

[0101] (2) Construction of key target network of Atractylodes macrocephala for the treatment of insomnia

[0102] A total of 6780 insomnia disease-related targets were obtained from drugbank, OMIM, and genecards databases. The 153 targets of Atractylodes lancea volatile oil were intersected with 6780 potential insomnia-related target genes by Venn 2.1.0, and 60 potential targets of Atractylodes lancea volatile oil for the treatment of insomnia were obtained ( Figure 6 ); The potential targets were imported into the STRING database to obtain the PPI network diagram, and then visualized by Cytoscape 3.9.1 software ( Figure 7 ).

[0103] (3) GO enrichment and KEGG pathway analysis

[0104] The 10 core targets of Atractylodes lancea for insomnia treatment were imported into the CTD (Comparative Toxicogenomics Database) database for enrichment analysis. The BP, MF, and CC enrichment entries were 136, 12, and 21, respectively, with pValue < 0.05 being statistically significant. The enrichment results showed that the GO functional enrichment results showed that Atractylodes lancea was involved in biological processes such as the ling pathway, coupled to cyclic nucleotide second messenger, chemical synaptic transmission, adenylate cyclase-inhibiting serotonin receptor signaling pathway, and xenobic catabolic process. Figure 8 ). KEGG results showed that a total of 105 candidate signaling pathways were obtained ( Fig. 9 ), mainly involving metabolic pathway signaling pathways, neuroactive ligand and receptor interaction signaling pathways, serotonergic synaptic signaling pathways, cAMP signaling pathways, chemical carcinogenesis-receptor activation signaling pathways, etc.

[0105] Fig. 9 Note: The X-axis represents the gene proportion, the Y-axis represents the KEGG signaling pathway name, the number of pathway enriched genes is represented by the bubble area, and the size of the P value is represented by the bubble color depth.

[0106] Embodiment 1

[0107] Microemulsion of Atractylodes lancea volatile oil as an auxiliary treatment for tranquilization of nerves

[0108] 1. Research Plan

[0109] 1. Grouping, modeling, and drug administration

[0110] C57BL mice were randomly divided into normal group, model group, positive drug group and low, medium and high dose groups of Atractylodes lancea volatile oil. There were 10 mice in each group. Except for the normal group, the other mice were gavaged with PCPA (300 mg / kg) for 3 consecutive days to induce insomnia model. During the modeling period, drugs were administered at the same time, and diazepam (1.3 mg / kg) was injected intraperitoneally in the positive group. The normal group and the model group were intraperitoneally injected with the corresponding volume of 0.9% sodium chloride solution, and the low, medium and high dose groups of Atractylodes lancea were administered by inhalation of incense, with the dosages of 23.4 mg / kg, 46.8 mg / kg and 93.6 mg / kg, respectively, once a day, for 10 consecutive days.

[0111] 2. Behavioral observation

[0112] During the experiment, the mental state, hair gloss, sleep and activity of each group of mice were observed and recorded.

[0113] 3. Righting reflex test

[0114] Each group of mice was intraperitoneally injected with 4.5 mg / mL sodium pentobarbital solution and laid supine on a flat board. After the mice entered a sleeping state, the sleep latency (the time from the injection of sodium pentobarbital to the disappearance of the righting reflex) and the sleep time (the time from the disappearance of the righting reflex to awakening) of the mice were observed.

[0115] 4. Mouse autonomous activity test

[0116] 30 minutes after the last administration, each group of mice was tested for autonomous activity. The mice were allowed to adapt to the environment for 5 minutes, and the number of mouse activities within 5 minutes was counted to compare the differences among the groups.

[0117] 5. Pathological HE staining sections of mouse brain tissue

[0118] After killing the mice, part of the brain tissue was taken, dissected and rinsed with pre-cooled saline to remove the contents, fixed with 4% paraformaldehyde solution, embedded in paraffin and stained with HE, and the target area was observed and selected for photographic analysis.

[0119] 6. ELISA detection of 5-HT, Glu, GABA, TNF-α, IL-2, IL-6 mRNA content in mouse brain tissue

[0120] One hour after the last administration, the eyeballs were removed to collect blood and then the mice were killed by dislocation. The cells were centrifuged at 3000 r / min for 15 min at 4°C to separate the serum, and the contents of 5-HT, Glu, GABA, TNF-α, IL-2, and IL-6 in the supernatant of mouse brain tissue homogenate were detected according to the ELISA instructions.

[0121] 7. RT-qPCR determination of cAMP, PKA, CREB, BDNF and TrKB in mouse brain tissue

[0122] Real-time fluorescence quantitative PCR (RT-qPCR) was used to detect the expression of core gene mRNA in mouse brain tissue. The mouse brain was treated with Trizol reagent to extract total RNA. RNA was reverse transcribed into cDNA using the ReverTraAce Q-PCRT MasterMix kit. β-actin was used as an internal reference. cDNA was used as a template for fluorescence quantitative detection of the mRNA expression level of the relevant target gene in each group of samples to obtain the Ct value of the sample to be tested. The experimental results were analyzed using 2 -ΔΔCt The expression levels of target genes were calculated using R software. The primer sequences are shown in Table 2.

[0123] Table 2: Primer sequences for RT-qPCR

[0124] Gene Upstream Downstream cAMP AGGTCCTCAGCTACAAGGAAG TCTTGAAGTCACAATCCTCTGGT PKA GGTGACAGACTTCGGTTTTGC CAGCTTTGTTGTAGCCTTTGC BDNF TGGGGTTAGGAGAAGTCAAGC GTCAGGTAACCACTAACACATTCG TrKB CAACTGACATCGGGGATACTACA CACAGAGGCAATCACCACCA CREB GCAGCAAGAGAATGTCGTAGAAA CCAATCCAGTCCATTTTCCA β-actin TTCGTTGCCGGTCCACACCC GCTTTGCACATGCCGGAGCC

[0125] 8. Western blotting to detect the expression of cAMP, PKA, CREB, BDNF and TrKB proteins in brain tissue

[0126] Brain tissues of mice in each group were taken, and RIPA lysis buffer containing phosphatase inhibitors and PMSF was added to extract total protein, and the protein concentration was determined according to the BCA kit. The protein samples were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to PVDF membrane, blocked with 5% skim milk at room temperature for 2 hours, and then the corresponding antibodies were added and incubated at 4°C overnight. Washed 3 times with PBST, added secondary antibodies, and incubated at room temperature for 2 hours. Washed 3 times with PBST, added ECL luminescent reagent for development, imaged using a gel imaging system, and analyzed the grayscale value of the bands using Image J software.

[0127] 9. Data Processing

[0128] SPSS 21.0 and Graph Pad Prism 6 were used for statistical analysis and Pearson correlation analysis. The t-test and one-way analysis of variance were used for comparison among the groups, and P < 0.05 was considered statistically significant.

[0129] 2. Animal Experiment Results

[0130] 1. General status

[0131] Before modeling, mice in each group had normal activities, shiny hair, good mental state, and weight gain. After 7 days of continuous modeling, mice in the model group showed day and night, decreased water intake, dry and slightly messy hair, dull and dull hair, erect hair, thin body, irritable temperament, irritability, and aggressiveness, indicating that the modeling was successful. After treatment with Atractylodes lancea volatile oil, the weight gain of mice increased, water intake gradually returned to normal, and hair regained its luster.

[0132] 2. Effect of Atractylodes lancea volatile oil on body weight of mice

[0133] As shown in Table 3, after 7 days, the weight of mice in the blank group increased; compared with the blank group, the weight of mice in the modeling group increased more before 7 days, and the weight gain from 7 to 10 days was significantly reduced (P < 0.05); after 10 days of treatment, compared with the model group, the weight gain of mice in the high, medium and low dose groups of Atractylodes lancea volatile oil was 2.33 times, 1.51 times and 2.7 times that of the model group, respectively (P < 0.05), and there was no significant difference between the high dose group of Atractylodes lancea volatile oil and the positive drug group. In summary, after the last administration, the high, medium and low doses of Atractylodes lancea volatile oil improved the symptoms of insomnia (P < 0.05).

[0134] Table 3: Effects of Atractylodes lancea volatile oil on body weight of insomnia model mice

[0135] Group Day 0 Day 7 Day 10 Day 20 Blank Group 20.16±0.23 20.75±0.57 22.13±0.54 24.10±0.81 Model Group 20.57±0.13 20.49±0.40 <![CDATA[19.55±1.21 # ]]> <![CDATA[20.77±0.67 # ]]> Positive group 19.12±0.09 20.72±0.47 21.61±0.71 <![CDATA[23.01±1.35 * <!-- 11 -->]]> Low dose group 20.01±0.31 20.61±0.57 20.60±0.64 <![CDATA[23.25±1.50 * ]]> Medium dose group 19.57±0.11 20.67±0.68 21.01±0.51 <![CDATA[22.94±1.21 * ]]> High dose group 20.84±0.12 21.25±1 20.38±0.61 <![CDATA[23.23±0.81 * ]]>

[0136] 3. Effect of Atractylodes lancea volatile oil on sleep in mice

[0137] As shown in Table 4, compared with the normal group, the sleep time of mice in the model group was significantly shortened (P<0.05), and the sleep latency was prolonged (P<0.01), indicating that the mice had insomnia symptoms and the model was successfully established; compared with the model group, the low, medium and high doses of positive drugs and Atractylodes lancea volatile oil groups could significantly shorten the sleep latency of mice (P<0.01), and the high doses of positive drugs and Atractylodes lancea volatile oil groups could also significantly prolong the sleep duration in a dose-dependent manner (P<0.01, P<0.05).

[0138] Table 4: Effects of Atractylodes lancea volatile oil on sleep latency and duration in mice

[0139] Group Latent time / min Sleep time / min Blank Group 3.74±0.17 36.07±5.33 Model Group <![CDATA[6.07±0.23 ## ]]> <![CDATA[14.37±4.27 # ]]> Positive group <![CDATA[4.00±0.49 ** ]]> <![CDATA[50.14±12.20 ** ]]> Low dose group 5.54±0.20 24.39±5.74 Medium dose group <![CDATA[5.01±0.41 ** ]]> <![CDATA[33.66±7.39 * ]]> High dose group <![CDATA[4.17±0.18 ** ]]> <![CDATA[46.69±10.13 ** ]]>

[0140] 4. Effects of Atractylodes lancea volatile oil on the spontaneous activities of mice

[0141] Compared with the model group, the spontaneous activity of mice in the positive group was significantly inhibited, and the number of activities decreased (P<0.05). The number of spontaneous activities of mice in each dose group of Atractylodes lancea volatile oil decreased, and there was a certain inhibitory trend in spontaneous activity, among which the high dose had a more obvious effect, but there was no statistical difference (P>0.05), as shown in Table 5.

[0142] Table 5: Effects of Atractylodes lancea volatile oil on the spontaneous activities of mice

[0143] Blank Group 144.55±8.35 Model Group <![CDATA[200.85±19.62 ## ]]> Positive group <![CDATA[150.20±18.06 ** ]]> Low dose group 192.50±13.24 Medium dose group <![CDATA[182.55±16.28 ** ]]> High dose group <![CDATA[161.65±16.26 ** ]]>

[0144] 5. Morphological changes in brain tissue of insomnia mice

[0145] Depend on Fig.10It can be seen that the brain tissue structure of mice in the normal group was basically normal, the cells were arranged neatly, the staining was clear and uniform, and there was no obvious apoptosis and necrosis. The brain tissue damage of mice in the model group was more obvious, the cells were loosely and disorderly arranged, the staining was fuzzy and uneven, and the cell gap was enlarged. Compared with the model group, the damage in the drug group was alleviated, and the cells were arranged neatly. Compared with the drug group, the hippocampal tissue of mice in the positive drug group was slightly damaged, and the cell arrangement was slightly more disordered than that in the drug group.

[0146] 6. ELISA method to determine the content of 5-HT, Glu, GABA, TNF-α, IL-2 and IL-6 in brain tissue

[0147] Depend on Fig.11 It can be seen that compared with the blank group, the 5-HT and GABA contents in the brain of the model group mice were significantly reduced, and the Glu, IL-1, IL-6 and TNF-α contents were significantly increased (P<0.01, P<0.05); compared with the model group, the Atractylodes lancea volatile oil group and the positive drug group could significantly increase the 5-HT and GABA contents, and the volatile oil high-dose group and the positive drug group could significantly reduce the Glu, IL-1, IL-6 and TNF-α contents (P<0.05, P<0.01). This indicates that diazepam and Atractylodes lancea volatile oil can upregulate 5-HT and GABA in the cerebral cortex and downregulate Glu, IL-1, IL-6 and TNF-α to exert a sedative and sleep-promoting effect. The above generally shows that Atractylodes lancea volatile oil has a regulatory effect on the main neurotransmitters that affect sleep.

[0148] 7. RT-qPCR detection of cAMP, PKA, CREB, BDNF and TrKB mRNA expression in brain tissue

[0149] Depend on Fig.12 It can be seen that compared with the blank group, the cAMP, PKA, CREB, BDNF and TrKB in the brain tissue of the model group mice were significantly decreased (P < 0.01). After drug treatment, compared with the model group, the cAMP, PKA, CREB, BDNF and TrKB in the serum of the high-dose Atractylodes lancea group mice were significantly increased (P < 0.01).

[0150] 8. Western blotting to detect the expression of cAMP, PKA, CREB, BDNF and TrKB proteins in brain tissue

[0151] According to Western blot results ( Fig.13 ) showed that compared with the blank group, the expression levels of cAMP, PKA, CREB, BDNF and TrKB proteins in the brain tissue of mice in the model group were significantly decreased (P < 0.01); compared with the model group, the expression levels of cAMP, PKA, CREB, BDNF and TrKB proteins in the brain tissue of mice were significantly increased after high-dose treatment with Atractylodes lancea volatile oil (P < 0.05).

[0152] Embodiment 2

[0153] Microemulsion of Atractylodes lancea volatile oil as an adjuvant treatment for depression

[0154] 1. Research Plan

[0155] 1. Animal grouping

[0156] After one week of adaptive feeding, 60 rats were randomly divided into a blank group, a model group, a positive drug group (fluoxetine hydrochloride) and atractylodes lancea volatile oil (low, medium and high doses) group, with 10 rats in each group. Except for the blank group, the other groups adopted the CUMS model.

[0157] 2. Establishment of depression rat model and drug administration

[0158] The idea of ​​"chronic unpredictable stimulation (CUMS)" was adopted to establish an animal model of depression in rats. The blank group did not receive any stimulation, but was given sufficient water and feed. The experimental rats in the other groups were subjected to a 3-week chronic unpredictable stimulation experiment, including: fasting (24h), water deprivation (24h), swimming in 4℃ ice water (10min), 45℃ hot water stimulation (10min), wet bedding (24h), cage tilted 45° (24h), day and night reversal (24h), tail suspension (20min), a total of 8 types. In order to ensure random unpredictability, a stimulation method was arranged every day, and the same stimulation did not appear continuously (at least 2 days apart), and the stimulation was continuous for 21 days. The drugs were administered while the model was being established. The positive group was intraperitoneally injected with fluoxetine hydrochloride (1.8 mg / kg), the blank group and the model group were intraperitoneally injected with the corresponding volume of 0.9% sodium chloride solution, and the low-, medium-, and high-dose groups of Atractylodes lancea were administered by inhalation of incense, with the dosages being 16.2 mg / kg, 32.4 mg / kg, and 62.8 mg / kg, respectively, once a day for 2 consecutive weeks.

[0159] 3. Evaluation of depressive-like behavior

[0160] (1) Sugar water preference experiment

[0161] The changes in sugar water intake reflect the anhedonia of rats, which is a core symptom of depression. After the first day, the animals were given a bottle of 1% sucrose water (200 mL) and a bottle of ordinary drinking water (200 mL). After 24 hours of fasting and water deprivation, a bottle of 1% sucrose water (200 mL) and a bottle of ordinary drinking water (200 mL) were placed on the mouse cage again, and the positions were swapped after 0.5 hours. After 24 hours of testing, the rats were taken out and weighed again to calculate the sugar water preference rate.

[0162] Sugar water preference rate (%) = sugar water consumption / water and sugar water consumption × 100%

[0163] (2) Open field test

[0164] The open field test is a classic behavioral experiment to detect the spontaneous activity behavior of rats. The experimental device is a rat open field reaction box with the specifications (length × width × height): 50cm × 50cm × 40cm. The middle area is framed by behavioral software, and the rats can move freely in the box. During the experiment, turn on the camera and place the rats in the same direction in the central area at the bottom of the open field box. After allowing them to adapt for 1 minute, the movement distance, average speed, and stationary time within 3 minutes are formally recorded. Before conducting the experiment on the next rat, remove the excrement first, wipe the device box with 75% alcohol, and then wipe it dry with a clean paper towel to avoid the original animal odor in the experimental device from interfering with the experimental results.

[0165] (3) Tail suspension test

[0166] The tail suspension test is a classic behavioral test that is widely used to assess the degree of depression and the response to antidepressant treatment. The rats were hung upside down, with their tails fixed on a horizontal wooden board 2 cm from the tip of the tail, and hung 30 cm above the table. The behavioral detection software was turned on and the video was recorded. During the experiment, the rats struggled to overcome the uncomfortable position, and the total hanging time was 6 minutes. The cumulative immobility time within 4 minutes after recording (the immobility state means that the rats stopped struggling and did not move or had no activity, and were in a "disappointed" state) and the extent of the rats' struggle was observed. After the experiment, the tail suspension box was carefully cleaned, and the bottom and inner wall of the tail suspension box were wiped with 75% alcohol to avoid the residual odor from affecting the next experiment.

[0167] (4) Forced swimming test

[0168] The forced swimming test is an effective behavioral test to evaluate the desperation behavior of rats. Prepare a cylindrical glass water tank with a height of 50 cm and a diameter of 20 cm. Fill it with water to a height where the rat cannot touch the bottom of the tank with its feet or tail during swimming and ensure that the rat cannot escape. The water temperature is measured with a thermometer (23-25℃). The experiment lasts for 6 minutes, and the total immobility time of the rat in the water is recorded for the last 4 minutes. After the experiment, take out the rat immediately, dry it on absorbent paper, and put it back into the cage.

[0169] 2. Animal Experiment Results

[0170] 1. General condition of rats

[0171] During the experiment, compared with the blank group, the rats in the model group showed symptoms such as loss of appetite, weight loss, listlessness, and dull fur color; compared with the model group, the rats in the medium and high dose groups of Atractylodes lancea volatile oil had improved appetite, spirit, and fur color, and their weight increased.

[0172] 2. Sugar water preference

[0173] As shown in Table 6, compared with the blank group, the sugar preference rate of rats in the model group was significantly reduced (P<0.01), indicating that the model was successfully established. Compared with the model group, the sugar preference rate of rats in the medium and high dose groups of Atractylodes lancea volatile oil and the positive drug group was significantly increased (P<0.05).

[0174] Table 6: Effect of Atractylodes lancea volatile oil on sugar water preference rate in depressed rats

[0175] Group Sugar water preference rate / % Tail suspension time / s Swimming immobility time / s Blank Group 86.58±4.37 95.99±7.19 130.05±14.24 Model Group <![CDATA[61.79±6.50 ## ]]> <![CDATA[175.41±7.80 ## ]]> <![CDATA[188.25±15.13 ## ]]> Positive drug group <![CDATA[84.43±6.60 ** ]]> <![CDATA[106.50±4.89 ** ]]> <![CDATA[150.4±11.57 ** ]]> Low dose group 64.62±5.53 <![CDATA[163.50±4.92 * ]]> 173.74±15.54 Medium dose group <![CDATA[74.48±5.58 * ]]> <![CDATA[132.13±4.13 ** ]]> <![CDATA[154.00±21.55 * ]]> High dose group <![CDATA[84.54±5.39 ** ]]> <![CDATA[103.75±4.18 ** ]]> <![CDATA[148.86±13.46 ** ]]>

[0176] 3. Open field experiment

[0177] like Fig.14 As shown in the figure, compared with the blank group, the total distance and average speed of the rats in the model group were significantly reduced (P<0.01), while the immobility time was significantly prolonged (P<0.01), indicating that the model was successfully established. Compared with the model group, the positive drug group and the high-dose Atractylodes lancea volatile oil group could significantly increase the total distance and average speed of the rats (P<0.01) and shorten the immobility time (P<0.01).

[0178] Table 7: Effects of Atractylodes lancea volatile oil on exercise in depressed rats

[0179] Group Total movement distance / cm Average speed / (cm / s) Static time / s Blank Group 756.32±64.89 4.2±0.36 39.53±6.28 Model Group <![CDATA[424.80±59.74 ## ]]> <![CDATA[2.39±0.29 ## ]]> <![CDATA[72.74±13.54 ## ]]> Positive drug group <![CDATA[693.11±133.93 ** ]]> <![CDATA[3.96±0.96 ** ]]> 43.07±9.88 Low dose group 560.73±70.95 3.12±0.39 54.25±15.86 Medium dose group <![CDATA[605.08±61.95 * ]]> 3.36±0.34 48.07±9.15 High dose group <![CDATA[668.22±87.43 ** ]]> <![CDATA[3.71±0.49 ** ]]> <![CDATA[40.51±4.33 ** ]]>

[0180] 4. Tail suspension test

[0181] Compared with the blank group, the immobility time of the model group rats was significantly increased (P<0.01), indicating that the model was successfully established. Compared with the model group, the immobility time of the positive drug and the high and medium dose groups of Atractylodes lancea volatile oil were significantly reduced (P<0.05, P<0.01), which had a certain improvement effect on the depression of rats.

[0182] Table 8: Effects of Atractylodes lancea volatile oil on tail suspension immobility time in depressed rats

[0183] Group Tail suspension time / s Blank Group 95.99±7.19 Model Group <![CDATA[175.41±7.80 ## ]]> Positive drug group <![CDATA[106.50±4.89 ** ]]> Low dose group <![CDATA[163.50±4.92 * ]]> Medium dose group <![CDATA[132.13±4.13 ** ]]> High dose group <![CDATA[103.75±4.18 ** ]]>

[0184] 5. Forced swimming test

[0185] Compared with the blank group, the immobility time of the rats in the model group was significantly increased (P<0.01), indicating that the model was successfully established. Compared with the model group, the immobility time of the rats in the positive drug and high and medium dose groups of Atractylodes lancea volatile oil was significantly decreased (P<0.05, P<0.01).

[0186] Table 9: Effects of Atractylodes lancea volatile oil on the immobility time of forced swimming in depressed rats

[0187] Group Swimming immobility time / s Blank Group 130.05±14.24 Model Group <![CDATA[188.25±15.13 ## ]]> Positive drug group <![CDATA[150.4±11.57 ** ]]> Low dose group 173.74±15.54 Medium dose group <![CDATA[154.00±21.55 * ]]> High dose group <![CDATA[148.86±13.46 ** ]]>

[0188] Although the present invention has been described with reference to preferred embodiments, various modifications may be made thereto and parts thereof may be replaced by equivalents without departing from the scope of the present invention. In particular, the various technical features mentioned in the various embodiments may be combined in any manner as long as there is no structural conflict. The present invention is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.

[0189] In the description of the present invention, the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer" and the like indicating directions or positional relationships are based on the directions or positional relationships shown in the drawings, which are only for the convenience of description, and do not indicate or imply that the device or element must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", and "third" are used for descriptive purposes only, and cannot be understood as indicating or implying relative importance.

[0190] In addition, it should be noted that in the description of the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For those skilled in the art, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0191] The term "comprise" or any other similar term is intended to cover a non-exclusive inclusion, such that a process, article, or apparatus / device that includes a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, article, or apparatus / device.

[0192] So far, the technical solutions of the present invention have been described in conjunction with the preferred embodiments shown in the accompanying drawings. However, it is easy for those skilled in the art to understand that the protection scope of the present invention is obviously not limited to these specific embodiments. Without departing from the principle of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will fall within the protection scope of the present invention.

Claims

1. A method for preparing a microemulsion of volatile oil of Atractylodes macrocephala, characterized in that: The following steps are involved: S1, selecting a surfactant and a co-surfactant and mixing them to form a mixed surfactant; S2. Mixing the Atractylodes lancea essential oil and the mixed surfactant according to a mass ratio, and preparing a microemulsion by titration.

2. The method for preparing a microemulsion of Atractylodes lancea volatile oil according to claim 1, characterized in that: The surfactant is selected from one or more of Tween-80, Tween-60, EL-35 and EL-30.

3. The method for preparing a microemulsion of Atractylodes lancea volatile oil according to claim 1, characterized in that: The co-surfactant is selected from one or more of anhydrous ethanol, PEG-400, propylene glycol and glycerol.

4. The method for preparing a microemulsion of Atractylodes lancea volatile oil according to claim 1, characterized in that: The surfactant and the co-surfactant are uniformly mixed in a mass ratio of 2:

1.

5. The method for preparing a microemulsion of Atractylodes lancea volatile oil according to claim 1, characterized in that: The mixed surfactant and the atractylodes lancea essential oil are mixed in a mass ratio of 1-9:9-1.

6. The method for preparing a microemulsion of Atractylodes lancea volatile oil according to claim 5, characterized in that: The volatile oil of Atractylodes lancea was used as the oil phase, deionized water was used as the water phase, Tween-80 was used as the surfactant, and anhydrous ethanol was used as the co-surfactant. The optimal Km value was 2.

7. The method for preparing a microemulsion of Atractylodes lancea volatile oil according to claim 1, characterized in that: The microemulsion solution is uniform, clear and transparent.

8. An application of the Atractylodes lancea volatile oil microemulsion according to claim 1, characterized in that: The atractylodes volatile oil microemulsion is a composition for assisting in the treatment of tranquility and depression.